New Molecular Targets for the Treatment of Neuropsychiatric Symptoms in Dementia


Date of CE Release: 03/04/2021

Date of CE Expiration: 03/04/2022

Learner Notification

 

Faculty:

Krista L. Lanctôt, PhD

Sunnybrook Health Science Center

AAGP 2021 Distinguished Scientist Award Recipient

 

Howard Aizenstein, MD, PhD

University of Pittsburgh

 

Summary: This presentation will review recent research on targets, pharmacotherapies and diagnostic criteria for neuropsychiatric symptoms in dementia.

 

UAN: JA4008163-9999-21-043-H04-P
Activity Type: Knowledge Based

Objectives for Webinar:

1. Participants will be able to identify current diagnostic criteria for apathy, agitation and psychosis in dementia

2. Participants will be able to identify new treatment targets for apathy, agitation and psychosis in dementia

3. Participants will be familiar with the efficacy of recent pharmacologic interventions for neuropsychiatric symptoms (NPS) in dementia

 

Acknowledgement of Support
This webinar is supported in part by an unrestricted educational grant provided by the American Board of Psychiatry and Neurology (ABPN).

 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Association for Geriatric Psychiatry.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians

Amedco LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

Nurses

Amedco LLC designates this activity for a maximum of1.0 ANCC contact hours.

 

Pharmacists

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

 

Psychologists

Amedco LLC designates this activity for a maximum of 1.0 psychologist contact hours. 

 

Click here for list of state boards accept courses from APA providers for Counselors, MFTs, Addictions Professionals, and Social Workers.

 

Social Workers

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social workers completing this course receive 1.0 GENERAL continuing education credits.

 

Click here for list of state boards accept courses offering ASWB ACE credit for Social Workers, Counselors, MFTs, and Addictions Professionals.

 

Disclosure of Relevant Financial Relationships:

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

 

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no relevant financial relationships.

 

Krista L. Lanctôt

ICG Pharma - Consultant

BioXcel Therapeutics - Scientific/Medical Advisory Board Member

Cerevel Therapeutics - Scientific/Medical Advisory Board Member

Kondor Pharma - Consultant

Howard Aizenstein

No relevant financial relationship exists



Reference list for March Webinar

 

Click here to complete the Webinar Post Test and CE Evaluation 

 

 

Back to webinar listing